The Week in Review: Shanghai Pharma Plans $1.2 Billion IPO

Shanghai Pharmaceuticals will raise 8 billion RMB ($1.2 billion) in a Hong Kong IPO; Roche plans to increase both its China investments and headcount; EntreMed raised $5.1 million in a private placement with a China marketing rights sweetener; Eisai Pharma began China marketing of Glufast®, a diabetes II drug; Bayer Schering launched its recombinant insulin, SciLin, in China; Skystar Bio-Pharma expects a new manufacturing facility to add $5 million in revenue; and China Sky One Medical reduced its guidance for 2010. More details…. Stock Symbols: (SHEX: 601607) (VS: ROG) (NSDQ: ENMD) (TSE: 4523) (XETRA: BAY) (NSDQ: SKBI) (NSDQ: CSKI)